IV thrombolysis is the only approved therapy for acute ischemic stroke. Clinical benefit for approximately 1 in 7 treated patients results when administered within 4.5 hours of stroke onset. 1, 2 The widespread use of IV thrombolysis is, however, hindered by symptomatic intracranial hemorrhage (sICH), which affects 2%-8% of patients (depending on the definition of sICH employed). While several factors clearly enhance the risk for sICH (such as age, NIH Stroke Scale score, and onset to treatment time), current data on the safety of IV thrombolysis in warfarin-treated stroke patients with subtherapeutic international normalized ratio (INR) are contradictory. [3] [4] [5] In the United States, warfarin-treated stroke patients are eligible for IV thrombolysis if their pretreatment INR is Յ1.7 and if they present within 3 hours from stroke onset. 6 In Europe, current treatment with anticoagulants is an absolute contraindication to IV thrombolysis according to the European Medicines Agency (EMA); this discrepancy has propagated the off-label use of IV thrombolysis in Europe among patients who would otherwise be considered eligible for treatment.
In this issue of Neurology ® , Ruecker and coauthors 7 present a prospective observational study on the risk of sICH and major systemic bleeding complications in thrombolyzed stroke patients with prior warfarin use and INR Յ1.7, in comparison to those not treated with warfarin. Applying predictive multivariable modeling, the authors showed that prior warfarin treatment (even at INR levels of Յ1.7) carries a considerable bleeding risk. In addition, the authors provide the reader with a clearly presented, accurate meta-analysis involving 4,856 patients and compare the heterogeneous data in the literature with their own findings. The authors enrolled 548 patients, of whom 15 (2.7%) received warfarin prior to stroke onset and had INR Յ1.7. Of these, 20% developed sICH and 1 additional patient (6.7%) had a major bleeding complication within 72 hours of IV thrombolysis. The odds for any major hemorrhage (systemic or intracranial) and sICH alone were 4.1 and 4.2, respectively. This risk remained almost unchanged after adjustments for age, initial NIH Stroke Scale score, and diabetes (all of which are independent risk factors for hemorrhage). Patients with prior warfarin therapy had a similar clinical outcome than those who were not on warfarin.
Although comparable to previous publications, 3, 4 the results of Ruecker and coworkers' study are a cause for concern. This is not just another singlecenter study, given that this report provides the first meta-analysis on this issue. The authors took special care to ascertain warfarin intake in their cohort and the different analyses employed to examine the relationship between warfarin intake and bleeding complications all arrived at the same conclusion. Furthermore, despite the heterogeneity of the data, the meta-analysis resulted in similar results: thrombolysis in stroke patients pretreated with warfarin carries a substantial risk of intra-and extracranial hemorrhage even when INR is Յ1.7. The potential explanations for the increased risk of hemorrhagic events presented in the discussion seem plausible as do the remarks on the heterogeneity of the included studies. Differing definitions of present warfarin intake (from 1 to 5 days before stroke onset) and varying quality control in ascertainment of warfarin intake may in part explain these contradictory findings. Also, the time intervals for the assessment of bleeding complications from stroke onset differed between studies. The authors also acknowledge several limitations to their study. Although the study was performed prospectively and included a considerable number of patients (n ϭ 548), the subsample of patients on warfarin is unfortunately small (n ϭ 15), raising concerns on the robustness of their analysis. This drawback-despite what the authors stated in their discussion-cannot simply be overcome by the addition of a meta-analysis.
Given the existent risk of hemorrhage for these patients, what conclusions should be drawn? The attitude toward thrombolytic treatment has changed in the past few years from being resistant to give thrombolytic therapy due to expected bleeding complications and perceived lack of benefit to regarded as ideal when indicated. 8, 9 Clearly, the decision for IV thrombolysis needs to be taken with caution in these patients. Information on stroke onset and eligibility for thrombolytic treatment needs to be confirmed for accuracy, and treatment guidelines (in particular, blood pressure control) strictly adhered to. Specific risk-benefit profiling tools in concordance with advanced imaging procedures may be of help to select individual patients who may most benefit from thrombolytic therapy if subtherapeutic warfarin treatment is present. 10 Moreover, specific precautionary measures need to be applied for early recognition of bleeding complications and their prompt treatment. In the current study, half of the patients with bleeding showed an INR rise above 1.7 6 hours after thrombolysis. It may perhaps be reasonable to repeat INR at regular intervals to determine whether the effects of warfarin persist or diminish following thrombolytic treatment. In Europe, the treating stroke physician has to be aware of applying an off-label therapy which has to be discussed judiciously with the patient or relatives to prevent possible legal problems.
Implications for further research include realization of larger-scale multicenter studies, assessment of the potential of serial INR to identify high-risk patients for bleeding events, and prospective assessment of outcomes in warfarin-treated patients who developed bleeding complications following IV thrombolysis. 
